Related by context. All words. (Click for frequent words.) 84 baseline CD4 76 nadir CD4 cell 74 CD4 + cell 73 CD4 cell 70 baseline CD4 + 70 cells μL 69 cells mcL 68 cells uL 67 antiretroviral naïve 67 cells/mm3 67 neutrophil count 66 absolute lymphocyte 66 mm ³ 66 lymphocytosis 65 -#.# log# copies mL 65 log# copies mL 64 CD4 + 64 HIV RNA 64 lymphocyte count 64 CD3 + 64 REYATAZ r arm 64 pT3 63 genotype 1b 63 HBeAg negative patients 63 undetectable viral load 63 leukocyte count 63 leukocytosis 63 seroconverted 62 undetectable HBV DNA 62 antiretroviral naive 62 antibody titer 62 specific antigen PSA 62 -#.# log# 62 CD4 T 62 virologic failure 62 achieved sustained virological 62 mL/min/#.# m 2 62 baseline neutrophil counts 62 mg ustekinumab 62 relapsed MM 62 HBeAg seroconversion 62 biochemical relapse 62 experienced virologic failure 62 CD4 + T 61 achieved ACR# 61 CD4 lymphocytes 61 CD4 counts 61 % CI #.#-#.# [003] 61 BARACLUDE ® 61 neutrophil counts 61 Folfox 61 serum prostate 61 highest tertile 61 annualized relapse 61 pCR 61 leukopenia 61 CR nPR 61 ASCUS 61 ovarian carcinoma 61 lumbar spine BMD 61 seroconversion 61 μmol L 61 Pred Forte 61 Kaplan Meier analysis 61 treatment naļve 61 nonmetastatic 61 ng dl 61 evaluable subjects 61 anemia hemoglobin 60 del 5q MDS 60 receiving antiretroviral therapy 60 tipranavir r 60 PSA nadir 60 pmol L 60 atazanavir ritonavir 60 coinfected 60 TDF FTC 60 ug dose 60 HbA 1c levels 60 HOMA IR 60 Hb A1C 60 HER2 expression 60 ng dL 60 Flu Cy 60 lopinavir r arm 60 CC genotype 60 severe neutropenia 60 baseline LDH 60 lymphocyte counts 60 ± SD 60 aged ≥ 60 sustained virological response 60 undetectable viral 60 PASI scores 60 QTcF 60 undetectable viral loads 60 seropositivity 60 serum creatinine levels 60 plasma leptin 60 elevated transaminases 60 plasma folate 60 anti HBs 59 advanced neoplasia 59 copies ml 59 tipranavir ritonavir 59 heavily pretreated 59 % Confidence Interval 59 achieved CCyR 59 preoperative PSA 59 baseline A1C 59 HIV uninfected 59 KRAS mutations occur 59 underwent resection 59 placebo dexamethasone 59 serum PSA 59 moderate renal impairment 59 PSADT 59 naïve HCV 59 abacavir lamivudine 59 serum folate 59 HBV DNA levels 59 infliximab monotherapy 59 clodronate 59 anagrelide 59 CRp 59 HBV DNA 59 erythrocyte sedimentation rate 59 HbA1C levels 59 tumor histology 59 #.#ng/ml 59 plus OBT 59 CD4 lymphocyte count 59 underwent surgical resection 59 Viral load 59 mg/m2 dose 59 seroprotection 59 HIV HCV coinfected 59 complete cytogenetic response 59 umol L 59 XIENCE V demonstrated 59 operable breast cancer 59 remission CR 59 % CI #.#-#.# [008] 59 CIN3 58 endometrial thickness 58 mIU ml 58 Median PFS 58 HBeAg negative 58 mcg albinterferon alfa 2b 58 Breslow thickness 58 #mg ATC 58 papillary renal cell carcinoma 58 CCyR 58 ritonavir boosted 58 treatment naive genotype 58 mean ± SEM 58 virologic response 58 definite stent thrombosis 58 oxycodone CR 58 mRCC 58 Free Survival PFS 58 virus HBV 58 ACR# responses 58 advanced adenoma 58 stage IIIb IV 58 underwent liver transplantation 58 hemoglobin concentration 58 CD4 58 ALT elevation 58 hip BMD 58 prospectively stratified 58 thyroid carcinoma 58 serum estradiol 58 sUA 58 viral load 58 LEXIVA r 58 lactate dehydrogenase LDH 58 prostate carcinoma 58 dapagliflozin plus 58 Ishak fibrosis score 58 confidence interval #.#-#.# 58 genotypic resistance 58 histological subtype 58 mCi m 2 58 sustained virologic response 58 #mg BID [001] 58 tertile 58 virologic responses 58 castrate resistant 58 8mg/kg 58 mcL 58 visceral metastases 58 HBeAg 58 ertapenem 58 Platelet counts 58 serum HBV DNA 58 alanine aminotransferase 58 RBC folate 58 mmHg systolic 58 seronegative 58 liver histology 58 P = .# 58 XIENCE V PROMUS Stent 57 lowest tertile 57 virologic response EVR 57 univariate analysis 57 refractory NSCLC 57 attain statistical significance 57 microliter 57 hemagglutination inhibition 57 bortezomib refractory 57 serum testosterone 57 histologic subtype 57 MMSE score 57 treatment naïve genotype 57 CLL SLL 57 FOLFIRI alone 57 #mg q8h 57 BCG vaccinated 57 receiving ISENTRESS 57 HBsAg positive 57 estimated glomerular filtration 57 resected pancreatic cancer 57 mg QD 57 pg ml 57 autoantibody positive 57 systolic dysfunction 57 Viread Emtriva Sustiva 57 biochemical recurrence 57 extracapsular extension 57 euthyroid 57 aspartate aminotransferase AST 57 plasma HCV RNA 57 pT2 57 serum concentrations 57 IU ml 57 methotrexate monotherapy 57 clinico pathological 57 baseline Hb 57 interquartile range 57 hemoglobin concentrations 57 metastatic renal cell 57 nonnucleoside reverse transcriptase inhibitors 57 serum urate 57 Baseline characteristics 57 prospectively defined 57 absolute neutrophil count 57 NHANES III 57 galiximab 57 adefovir treated 57 mitoxantrone plus 57 genotype 1a 57 p = .# [002] 57 granulocyte 57 #.#/#.# mmHg [001] 57 KRAS mutations 57 virological response 57 nondiabetic patients 57 detectable HCV RNA 57 hemoglobin A1c HbA1c 57 oocytes retrieved 57 virologic suppression 57 null responder 57 grade squamous intraepithelial 57 Insulin sensitivity 57 elevated LDH 57 glycosylated hemoglobin levels 57 IU mL 57 creatinine ratio 57 splenectomized patients 57 HbA1c levels 57 mCRPC 57 HAQ DI 57 ECOG PS 57 Kaplan Meier estimates 57 multivariate Cox 57 fosamprenavir 57 triglyceride concentrations 57 urine albumin 57 HBeAg positive 57 morphometric vertebral fractures 57 progression TTP 57 μg dose 57 lopinavir r 57 hours postdose 57 VELCADE melphalan 57 Arch Intern Med 57 CD# upregulation 57 Index CDAI 57 de novo AML 57 hepatitis C genotype 57 deep venous thromboses 57 median survivals 57 localized renal 57 Cutaneous T 56 Secondary efficacy endpoints 56 comparator arm 56 mcg BID 56 achieved sustained virologic 56 hypogonadal 56 cEVR 56 peripheral blood mononuclear 56 baseline FEV 56 endoscopic remission 56 mg RDEA# 56 LV dysfunction 56 ® emtricitabine 56 nucleoside naive 56 HBsAg 56 adjuvant cisplatin 56 cubic millimeter 56 #Gy 56 recurrent glioblastoma multiforme 56 pegylated interferon alpha 56 seropositive 56 EDSS scores 56 HBeAg positive patients 56 femoral neck BMD 56 mcg dose 56 baseline serum creatinine 56 ALT flares 56 dose cohort 56 lopinavir ritonavir Kaletra 56 Treatment Naive Patients 56 TPV r 56 inhibin B 56 pancreatic adenocarcinoma 56 % CI #.#-#.# [006] 56 copies mL 56 adenoma recurrence 56 mg qd 56 DAS# remission 56 serum urate levels 56 baseline HbA1c 56 metastatic GIST 56 mmHg diastolic 56 underwent CABG 56 dalteparin 56 prostate cancer CaP 56 Multiple Myeloma MM 56 pmol liter 56 serum ALT 56 antibody titers 56 Partial Responses 56 -#.# mg dL [002] 56 CD4 count 56 rFSH 56 â ‰ ¥ 56 Doxil ® 56 corticosteroid dose 56 renal cell carcinomas 56 HCV Genotype 56 pegylated interferon alfa 2b 56 radical prostatectomy RP 56 apolipoprotein B 56 dehydroepiandrosterone sulfate 56 undetectable HCV RNA 56 Pharmacokinetics PK 56 haematological toxicity 56 posttreatment 56 posttransplant 56 #mg QD [002] 56 poor metabolizers 56 BENICAR HCT 56 cART 56 3TC lamivudine Epivir 56 paclitaxel cisplatin 56 creatinine levels 56 ErbB2 positive 56 mcg doses 56 IL#B 56 fructosamine 56 Chronic Hepatitis C 56 chlorambucil 56 #mg BID [003] 56 virologic failures 56 lactate dehydrogenase 56 HCV infected 56 DAS# [002] 56 recurrent venous thromboembolism 56 virological failure 56 thyrotropin levels 56 creatinine clearance 56 Viral Load 56 Naive Patients 56 ALT normalization 56 hemoglobin A1c levels 56 mg TID 56 Crohn Disease Activity 56 demonstrated antitumor activity 56 #mmHg [001] 56 monoinfected 56 HbA1C 56 binary restenosis 56 APTIVUS r 56 HLA A2 56 alanine aminotransferase ALT 56 HCV RNA 56 K ras mutations 56 FOLPI 56 serum aminotransferase levels 56 Stage IIIb 56 RRM1 56 atypical hyperplasia 56 certolizumab 56 CI #.#-#.# [001] 56 Relapsed Refractory 56 HIV seronegative 56 Follicular Lymphoma 56 NNRTI resistance 56 HER2 overexpression 56 elevated ALT 55 CD# + [001] 55 histologically confirmed 55 microalbumin test 55 log# IU mL 55 4mg/kg 55 eosinophil count 55 mm3 55 hydroxyvitamin D levels 55 abnormal cytology 55 #OHD levels 55 HGPIN 55 evaluable 55 multivariable analysis 55 PREZISTA r arm 55 atheroma volume 55 microalbumin 55 hemoglobin Hb 55 seminal vesicle invasion 55 Subgroup analysis 55 mL/min/#.# m2 55 -#.# ± [002] 55 CD# + [002] 55 Adenomas 55 mm Hg diastolic 55 Multicenter AIDS 55 sUA levels 55 onset idiopathic hypogonadism 55 fasting insulin 55 mg kg dose 55 clinically evaluable 55 uninfected infants 55 gemcitabine carboplatin 55 recurrent VTE 55 nmol liter 55 systolic blood pressures 55 FOLFOX4 55 flutamide 55 plus methotrexate 55 FOLFOX6 55 biliary tract cancer 55 elevated hsCRP 55 low dose Iluvien 55 3mg/kg 55 doxorubicin cyclophosphamide 55 doxorubicin docetaxel 55 tenofovir emtricitabine 55 ribavirin therapy 55 adiponectin concentrations 55 #q# deletion syndrome 55 CD4 + cells 55 Inhibin B 55 mmol l 55 undergone radical prostatectomy 55 adjunctive placebo 55 HCV genotype 1 55 g dl 55 HBV infections 55 glycosylated hemoglobin HbA1c 55 vincristine doxorubicin 55 confidence intervals CIs 55 microlitre 55 lymphopenia 55 invasive carcinomas 55 endometrioid 55 serum clusterin levels 55 β blocker 55 nonfasting triglyceride levels 55 #mg dose [002] 55 rimonabant #mg 55 % CI #.#-#.# [007] 55 median PFS 55 ATV RTV 55 seropositive patients 55 DAS# CRP 55 log# reduction 55 HIV coinfected 55 seminoma 55 mg kg Hematide 55 abnormal p# biomarker 55 microbiologically evaluable 55 troponin T 55 HCV genotype 55 Histologic 55 WOMAC pain 55 #.#mg/dL 55 HMG CoA reductase inhibitory 55 EGFR mutation positive 55 T1c 55 FTC TDF 55 prior chemotherapy regimens 55 Primary endpoints 55 FOLFOX4 alone 55 platelet reactivity 55 evaluating tivozanib 55 advanced adenomas 55 hepatocellular carcinomas 55 relapsed AML 55 multivariable adjusted 55 postintervention 55 PCA3 scores 55 EGFR TKI 55 telomere lengths 55 IFN α 55 dexamethasone Decadron 55 IQR 55 serum albumin 55 limiting generalizability 55 titers 55 iPTH 55 nondiabetic 55 HER2 negative 55 ritonavir boosted atazanavir 55 dosing cohort 55 lenalidomide Revlimid R 55 elevated troponin 55 decompensated liver disease 55 lamivudine refractory patients 55 LHRH receptor positive 55 Cmax 55 BMI z 55 T1a 55 osteopenic 55 ABC/3TC 55 antiangiogenic therapy 55 chronic HBV 55 CI -#.# 55 SUVmax 55 plus dexamethasone 55 hematopoietic cancers 55 homocysteine concentrations 55 viral titers 55 daily subcutaneous injections 55 serum antibody 55 Kaplan Meier 55 NIHSS 55 hsCRP levels 55 EURIDIS 55 transaminase levels 55 μg ml 55 IELT 55 TT genotype 55 enfuvirtide 55 folate concentrations 55 intramuscular dose 55 mEq L 55 epithelial ovarian cancer 55 Soft Tissue Sarcoma 55 biopsy Gleason 55 leukocyte counts 55 serum phosphate 55 lamivudine monotherapy 55 μg L 55 irinotecan cisplatin 55 low dose cytarabine 55 TIMP 1 55 nonobese 55 hematologic toxicity 55 HYVET 55 FluCAM arm 55 argatroban 55 pretransplant 55 A1c levels 55 bFGF 55 complete cytogenetic 55 normal karyotype 55 MELD scores 55 MetS 54 HCV antibody 54 interferon alfa 2a 54 nadroparin 54 potent antiretroviral therapy 54 baseline PASI 54 Renal Cell Carcinoma RCC 54 KRAS mutant tumors 54 tumors GIST 54 bone marrow reticulin deposition 54 initiating antiretroviral therapy 54 squamous histology 54 p = #.# [003] 54 aspartate aminotransferase 54 leucopenia 54 RECORD1 54 Retreatment 54 estramustine 54 + PH# 54 preintervention 54 heFH 54 log# 54 serum IGF 54 receiving Vectibix monotherapy 54 symptomatic intracerebral hemorrhage 54 invasive ductal 54 non squamous histology 54 Response Evaluation Criteria 54 MADRS score 54 e antigen HBeAg 54 6MWD 54 XL# administered orally 54 serum lipid levels 54 coinfection 54 CIMZIA TM certolizumab pegol 54 dose escalation phase 54 mutated K ras 54 non splenectomized 54 BRCA1 mutation carriers 54 nanomolar 54 EDSS score 54 fasting triglyceride levels 54 NIH CPSI 54 hormone receptor negative 54 Infected Patients 54 postoperative chemotherapy 54 ± SEM 54 ADAS cog 54 assessing T DM1 54 NIHSS score 54 BRCA mutation carriers 54 patients coinfected 54 achieved PASI 54 Secondary endpoints include 54 mcg linaclotide 54 nucleotide analog 54 ADCS ADL 54 mg m² 54 breast carcinoma 54 receiving INTRON 54 albumin excretion 54 mcg kg REBETOL 54 urinary N telopeptide 54 PROSTVAC VF 54 circulating endothelial cells 54 nonpregnant women 54 methylmalonic acid 54 Immunohistochemical staining 54 underwent radical prostatectomy 54 adult chronic ITP 54 HBeAg + 54 receiving VICTRELIS 54 NRTI resistance 54 intact parathyroid hormone 54 μg doses 54 Scale EDSS 54 insulin detemir 54 pegIFN 54 MVax R 54 #mg/day [001] 54 nonvertebral fractures 54 cytogenetic response 54 Castration Resistant Prostate Cancer 54 antiandrogen 54 odds ratios ORs 54 NSABP B 54 Systemic Sclerosis 54 tPSA 54 Operative mortality 54 CIN2 + 54 Alzheimer Disease Assessment 54 Peginterferon 54 T2DM 54 RLAI 54 completely resected 54 Kaplan Meier method 54 rs# [001] 54 tirofiban 54 FluCAM 54 R# #mg BID 54 iniparib BSI 54 viral loads 54 anastrazole 54 microg 54 PREZISTA ritonavir 54 CD8 + lymphocytes 54 IRLS score 54 gastric carcinoma 54 bioavailable testosterone 54 Hepsera adefovir dipivoxil 54 osteosarcomas 54 highest quintile 54 confirmed CCyR 54 efavirenz emtricitabine 54 ANCOVA 54 CR CRu 54 serum CRP 54 KRAS wild 54 statistically significant p = 54 Viread Emtriva 54 specific alkaline phosphatase 54 polyp recurrence 54 metastatic lung cancer 54 concentration Cmax 54 clinically meaningful improvement 54 previously untreated follicular 54 REYATAZ r 54 mg BID dose 54 cisplatin vinorelbine 54 plus COPEGUS 54 azilsartan medoxomil 54 HI titers 54 myelodysplastic myeloproliferative diseases 54 atorvastatin #mg 54 colorectal carcinoma 54 blood glucose concentrations 54 peginterferon alfa 2b 54 paclitaxel eluting stents 54 cubic milliliter 54 indinavir 54 Univariate analysis 54 plus prednisone 54 NMIBC 54 p# biomarker 54 mcg QD 54 glycated hemoglobin HbA1c 54 K#N 54 enteroviral infection 54 cervix uteri 54 distant metastasis 54 chronic HCV genotype 54 gastric adenocarcinoma 54 FDG-PET/CT 54 pg mL 54 FDA defined valvulopathy 54 Median progression 54 CHD mortality 54 undergoing hematopoietic stem 54 J Clin Oncol 54 partial remissions 54 undetectable virus HCV 54 postmenopausal osteoporotic women 54 statistical significance p 54 prednisone prednisolone plus 54 Aptivus ® 54 colorectal adenoma 54 chemoradiation therapy 54 epirubicin cyclophosphamide 54 Lupuzor ™ 54 hematological parameters 54 Index CDAI score 54 RECIST Response Evaluation Criteria 54 mITT population 54 CI #.#-#.# [002] 54 coinfected patients 53 octreotide LAR 53 μg liter 53 AZT 3TC 53 mcg Albuferon 53 undergone splenectomy 53 Partial Response 53 ACR# response 53 systolic BP 53 VIRAMUNE R 53 microvessel density 53 aminotransferase levels 53 lipid elevations 53 dose dexamethasone 53 aminotransferase 53 protein excretion 53 huN# DM1 53 lipid lowering medications 53 Leukemias 53 epithelial ovarian 53 T2 lesion volume 53 LPV r 53 virologically suppressed 53 estimated GFR 53 TOP2A 53 external genital lesions 53 hip resurfacing arthroplasty 53 atypical ductal hyperplasia 53 tryptase 53 seroprotective 53 mRS 53 HER2 homodimer levels 53 colorectal cancer incidence 53 glycated hemoglobin levels 53 Zometa hazard 53 tertiles 53 rizatriptan 53 transiently transfected 53 mg Lucentis 53 saline placebo 53 minimally symptomatic metastatic castrate 53 endometrial adenocarcinoma 53 TEAEs 53 oral FTY# 53 serum calcium levels 53 null responder HCV 53 NRTI sparing 53 melphalan prednisone 53 HIV seroconversion 53 BCIRG 53 uM 53 hepatoma 53 hematological relapse 53 #.#/#.# mm Hg [003] 53 febrile neutropenia 53 RNA copies mL 53 axillary node 53 nevirapine Viramune 53 MAGE A3 ASCI 53 placebo PBO 53 retrospectively analyzed 53 metastatic renal cell carcinoma 53 SHBG levels 53 Neutropenia 53 generalized edema 53 Median survival 53 albumin excretion rate 53 oral antidiabetic medication 53 p = NS 53 nonsignificant difference 53 serum cortisol 53 #mg/m# [001] 53 SORT OUT III 53 follicular lymphomas 53 mitoxantrone chemotherapy 53 q#h 53 parous women 53 cytokeratin 53 decitabine 53 dacarbazine DTIC 53 PASI score 53 -#.# mg dL [001] 53 mg BID 53 YMRS 53 urate lowering therapy 53 bronchoalveolar lavage fluid 53 Score DAS# 53 efficacy evaluable 53 serum IgE 53 μg mL 53 Durezol 53 Ki# 53 heterozygotes 53 q8h 53 LDH lactate dehydrogenase 53 arterial thickening 53 NPH insulin 53 aminotransferase ALT 53 lung ovary 53 g dL 53 CDAI score 53 PEG IFN 53 fasting glucose levels 53 rapid virologic response 53 alfa 2a 53 Amgen Neulasta ® 53 HNSCC 53 stage IIIB IV 53 leukemia AML 53 Randomized Phase II 53 5 Fluorouracil 53 serum HCV RNA 53 5-FU/LV 53 Stage IIB 53 pegylated liposomal doxorubicin 53 HER2 positive cancers 53 Prostate Specific Antigen 53 serum phosphate levels 53 UGT#A# * 53 plasma pharmacokinetics 53 AZT zidovudine Retrovir 53 mean baseline A1C 53 IPSS 53 DAS# scores 53 asymptomatic metastatic 53 receiving immunosuppressive therapy 53 Relapsed Refractory Multiple Myeloma 53 virologically 53 dosing cohorts 53 docetaxel pretreated 53 multivariate analyzes 53 response CCyR 53 NRTI backbone 53 preoperative chemotherapy 53 cisplatin resistant 53 drank pomegranate juice 53 mm Hg systolic 53 μg kg 53 #OHD 53 mammographic density 53 PANSS scores 53 Ann Intern Med 53 undergone hysterectomies 53 glulisine 53 RBC transfusion 53 μg d 53 fasting plasma glucose FPG 53 peginterferon alfa 53 BRIM2 53 R abatacept 53 esophageal carcinoma 53 virological suppression 53 CIMZIA TM 53 PEG Interferon alfa 53 allele frequencies 53 Telintra 53 reactogenicity 53 metastatic malignant 53 timepoints 53 buprenorphine implants 53 Pegasys plus Copegus 53 SCIg 53 placebo fluoxetine 53 paricalcitol 53 paraprotein 53 patients evaluable 53 R entecavir 53 breast carcinomas 53 arterial thromboembolic events 53 p#HER# positive 53 NCT# ClinicalTrials.gov 53 serodiscordant couples 53 Non inferiority 53 tipranavir 53 Protease inhibitor 53 Peginterferon Alfa 2a 53 HER2 amplified 53 univariate analyzes 53 suboptimal adherence 53 unprotected receptive anal 53 daunorubicin 53 mediated immunity 53 SLNB 53 Virologic 53 glomerular filtration rate 53 IFN alfa 53 nonadherent 53 undetectable hepatitis C 53 COPEGUS ribavirin 53 FUSILEV enhances 53 ALT elevations 53 HDRS 53 mIU L 53 colorectal adenomas 53 MCyR 53 reduce serum phosphate 53 Hemodialysis Patients 53 CTAP# Capsules 53 iPrEx study 53 HSCT 53 adjunctive ABILIFY 53 stage IIIB 53 elevated LDL cholesterol 53 hepatorenal syndrome 53 highly emetogenic 53 urothelial carcinoma 53 cGy 53 achieve sustained virological 53 LDL cholesterol HDL cholesterol 53 weekly subcutaneous injections 53 GSTP1 53 mg q#h 53 chlamydial infection 53 Zidovudine Tablets 53 darunavir 53 resistant hormone refractory 53 renal pelvis 53 dacarbazine chemotherapy 53 intravenous bolus 53 oral allopurinol 53 RECIST criteria 53 Solid Tumors RECIST 53 CHOP chemotherapy 53 CANCIDAS 53 N telopeptide 53 cisplatin chemotherapy 52 sero positive 52 nonvertebral fracture 52 rectal gonorrhea 52 lymphovascular invasion 52 MGd 52 Kaplan Meier survival 52 MMSE scores 52 eGFR 52 glomerular filtration 52 Secondary endpoints 52 locoregional disease 52 noncarriers 52 attending antenatal clinics 52 retrospective cohort 52 antithymocyte globulin 52 locoregional recurrence 52 transaminase elevations 52 Phase 2b Clinical Trial 52 onset diabetes mellitus 52 Scale EDSS score 52 Neutrophil